AA
CLVS

ALPS Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

ALPS Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-65,739
Closed -$3.47M – 979
2018
Q1 		$3.47M Buy
65,739
+11,425
+21% +$667K 0.03% 171
2017
Q4 		$3.69M Buy
+54,314
New +$3.8M 0.03% 153
2016
Q4 		– Sell
-49,083
Closed -$1.77M – 740
2016
Q3 		$1.77M Sell
49,083
-4,841
-9% -$104K 0.01% 191
2016
Q2 		$740K Buy
53,924
+10,828
+25% +$158K 0.01% 216
2016
Q1 		$827K Sell
43,096
-7,385
-15% -$156K 0.01% 196
2015
Q4 		$1.77M Sell
50,481
-8,354
-14% -$539K 0.02% 185
2015
Q3 		$54.1K Buy
58,835
+25,079
+74% +$2.17M 0.06% 108
2015
Q2 		$2.97M Buy
33,756
+16,810
+99% +$1.44M 0.03% 143
2015
Q1 		$1.26M Buy
+16,946
New +$1.2M 0.01% 174

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return